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COMMUNICATIONS
Constitutional or biallelic?
Settling on a name for a
recessively inherited cancer
susceptibility syndrome
Homozygous or compound heterozygous,
that is, biallelic, germ-line mutations in
one of the four mismatch repair (MMR)
genes cause a rare condition that has only
recently been recognised as a distinct
childhood cancer susceptibility syndrome.
As such there is still a lack of awareness of
the condition among paediatric oncolo-
gists. Timely recognition of the condition
that results in an extraordinarily high
cancer risk also has far-reaching conse-
quences for other family members. It is
therefore important that the medical and
scientific community reaches agreement
on a standard name for this condition,
because the use of different names could
potentially create confusion. It is for this
reason that we wish to comment on a new
designation for this recessively inherited
condition that was proposed in a recent
paper by Shlien et al.1
Retrospectively, it now seems almost
certain (although not proven genetically)
that the first patients with this cancer syn-
drome were described by Turcot et al.2
However, analysis of, so far, some 150
patients with biallelic inactivating mutations
in one of the four MMR genes, MLH1,
MSH2, MSH6 and PMS2, shows that
tumour spectrum of this cancer predispos-
ition syndrome is much broader than that
of Turcot syndrome.3 Therefore, the com-
prehensive designation ‘mismatch repair-
deficiency syndrome’ that alluded to the
underlying pathogenic mechanism of the
condition became the most widely used
name. In a review article summarising the
then current understanding of the condi-
tion, this designation originally coined by
Scott et al4 was extended to ‘constitutional
mismatch repair-deficiency’ in order to
avoid possible confusion with the somatic
mismatch repair-deficiency found in Lynch
syndrome-related tumours and sporadic
tumours associated with MLH1 hyper-
methylation.5 The amended name, ‘consti-
tutional mismatch repair-deficiency’, has
now been used in approximately 30
publications. Moreover, the senior author
of the Shlien et al publication, Uri Tabori,
founded and leads the international consor-
tium originally named the ‘constitutional
mismatch repair deficiency consortium’.6
We therefore find it difficult to under-
stand why this condition should now be
renamed to ‘biallelic mismatch repair defi-
ciency’ syndrome. MMR deficiency may
be limited to somatic neoplastic cells or
may already be present at the zygote stage
and consequently affect all cells of an indi-
vidual, explaining the term ‘constitu-
tional’, whereas ‘biallelic’ simply refers to
the MMR gene mutation status that causes
the condition—but such biallelic mutations
could be germ-line or somatic in origin.
Moreover, ‘mismatch repair deficiency’ is
a phenotype, whereas ‘biallelic’ refers to
the genotype. Hence, the specification
‘constitutional’ is far more precise.
Furthermore, the term used by OMIM to
describe the condition, ‘mismatch repair
cancer syndrome’ (OMIM #276300), the
use of which is in fact limited to OMIM,
also lacks the essential designation that
indeed deficiency of MMR capacity leads
to cancer predisposition. Based on the
above, we would argue that ‘constitutional
mismatch repair deficiency’ (recently
abbreviated to CMMRD, rather than
CMMR-D, for improved ease of use) is the
most appropriate name for the syndrome
and we strongly advocate that the medical
and scientific community continues to
adhere to its use in all future reports.
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